ArticleFrontiers in immunology2026
Decoupling of maternal and neonatal inflammatory levels at the maternal-fetal interface: evidence from a population-based proteomic study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mincle Receptor Deficiency Protects Against LPS-induced Preterm Birth and Fetal Inflammatory Response Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Maternal inflammation during pregnancy has been linked to offspring physical and neurodevelopmental health. This association has been hypothesized to operate through fetal immune responses. Yet, population-based evidence exploring the relationship between maternal and neonatal inflammation remains limited. This study investigates the associations of maternal inflammatory markers measured in the third trimester and at birth with neonatal inflammatory profiles at birth. Methods: Interleukin (IL)-1β, IL-6, IL-17a (pg/mL), and CRP (mg/L) levels were measured in maternal plasma at birth and in the third trimester and standardized for the at-birth and third-trimester subset. In the neonates, 92 inflammatory markers were measured in Dried Blood Spots using Olink Results: Maternal IL-1β, IL-6, IL-17a, and CRP levels measured at birth (n=194 mother-child dyads) or in the third trimester (n=235) were not significantly associated with levels of any of the 92 neonatal inflammatory markers. Effect estimates were small, and no associations survived FDR correction (FDR <0.05). Findings were observed with robust parsimonious adjustment for covariates and were similar across both maternal sampling timepoints. Conclusion: Maternal inflammation measured at birth and in the third trimester was not significantly associated with widespread changes in neonatal peripheral inflammatory profiles. These findings suggest that low-grade maternal inflammation may not elicit detectable systemic inflammatory responses in neonates at birth in a general population sample. Future research should replicate our findings and assess the role of neonatal inflammatory markers in subsequent offspring health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.